Credit Suisse First Boston is the lead manager on Royalty Pharma’s pending pharmaceutical patent-backed deal, currently in the marketing stages. This transaction, a follow-up to the Zerit-backed BioPharma Royalty Trust I, is said to be backed by a broader pool of patents. WestLB London agented the first transaction (see ASR 3/24).

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.